A patient with melanoma that became sensitized to immunotherapy after treatment with a CDK4/6 inhibitor.
A patient with melanoma that became sensitized to immunotherapy after treatment with a CDK4/6 inhibitor.
- 2020
Background: Despite the profound effect that checkpoint inhibitors and BRAF/MEK inhibitors have had on survival in patients with metastatic melanoma, treatment options remain limited for those who demonstrate poor response or develop resistance to these modalities. The prospect of tumor sensitization to these treatments is therefore an attractive one. Results: We describe the case of a patient who developed a sustained response to trametinib and pembrolizumab, despite prior resistance to both these therapies, after receiving treatment with a CDK4/6 inhibitor. Discussion: We further outline the preclinical data supporting a possible role for the use of CDK4/6 inhibitors in tumor sensitization to immunotherapy.
English
1750-743X
10.2217/imt-2020-0139 [doi]
*Antibodies, Monoclonal, Humanized/tu [Therapeutic Use]
*Antineoplastic Agents/tu [Therapeutic Use]
*Imidazoles/tu [Therapeutic Use]
*Immunotherapy/mt [Methods]
*Melanoma/dt [Drug Therapy]
*Oximes/tu [Therapeutic Use]
*Pyridones/tu [Therapeutic Use]
*Pyrimidinones/tu [Therapeutic Use]
Antibodies, Monoclonal, Humanized/im [Immunology]
Antineoplastic Agents/im [Immunology]
Cyclin-Dependent Kinase 4/ai [Antagonists & Inhibitors]
Cyclin-Dependent Kinase 4/im [Immunology]
Cyclin-Dependent Kinase 6/ai [Antagonists & Inhibitors]
Cyclin-Dependent Kinase 6/im [Immunology]
Humans
Imidazoles/im [Immunology]
Male
Melanoma/im [Immunology]
Middle Aged
Oximes/im [Immunology]
Pyridones/im [Immunology]
Pyrimidinones/im [Immunology]
Treatment Outcome
MedStar Washington Hospital Center
Internal Medicine Residency
Pathology Residency
Journal Article
Background: Despite the profound effect that checkpoint inhibitors and BRAF/MEK inhibitors have had on survival in patients with metastatic melanoma, treatment options remain limited for those who demonstrate poor response or develop resistance to these modalities. The prospect of tumor sensitization to these treatments is therefore an attractive one. Results: We describe the case of a patient who developed a sustained response to trametinib and pembrolizumab, despite prior resistance to both these therapies, after receiving treatment with a CDK4/6 inhibitor. Discussion: We further outline the preclinical data supporting a possible role for the use of CDK4/6 inhibitors in tumor sensitization to immunotherapy.
English
1750-743X
10.2217/imt-2020-0139 [doi]
*Antibodies, Monoclonal, Humanized/tu [Therapeutic Use]
*Antineoplastic Agents/tu [Therapeutic Use]
*Imidazoles/tu [Therapeutic Use]
*Immunotherapy/mt [Methods]
*Melanoma/dt [Drug Therapy]
*Oximes/tu [Therapeutic Use]
*Pyridones/tu [Therapeutic Use]
*Pyrimidinones/tu [Therapeutic Use]
Antibodies, Monoclonal, Humanized/im [Immunology]
Antineoplastic Agents/im [Immunology]
Cyclin-Dependent Kinase 4/ai [Antagonists & Inhibitors]
Cyclin-Dependent Kinase 4/im [Immunology]
Cyclin-Dependent Kinase 6/ai [Antagonists & Inhibitors]
Cyclin-Dependent Kinase 6/im [Immunology]
Humans
Imidazoles/im [Immunology]
Male
Melanoma/im [Immunology]
Middle Aged
Oximes/im [Immunology]
Pyridones/im [Immunology]
Pyrimidinones/im [Immunology]
Treatment Outcome
MedStar Washington Hospital Center
Internal Medicine Residency
Pathology Residency
Journal Article